cancer center News
-
NeoTherma Oncology Opens Clinical Study - Wichita, Kansas
NeoTherma Oncology, having achieved both FDA approval for its Investigational Device Exemption for an Early Feasibility Study of the VectRx™ System and institutional review board approval at an east coast National Cancer Institute-designated Cancer Center, has initiated recruitment for a first-in-human trial in patients with pancreatic ...
-
New Strategic Partnership with the University of Missouri Research Reactor Center (MURR)
ABK Biomedical Inc. (ABK) is pleased to announce a new multi-year strategic partnership with the University of Missouri Research Reactor Center (MURR®). MURR is the pre-eminent global leader in research reactors, with extensive experience supplying medical isotopes and irradiation services for medical devices. MURR is a key partner for ABK to establish seamless manufacturing, supply, and ...
-
Toxicity Atlas presentation CCA Conference
Last Friday, Medstoner Silvia presented the main findings of her first manuscript at the 5th Cancer Center Amsterdam (CCA) Conference! The manuscript entitled “A roadmap to use non-structured data to discover multi-target cancer vulnerabilities” highlights the lack of consistency in the currently available public data and discusses the importance of extracting information from ...
-
Monarch Platform Featured on Cover of Oncology Issues
The Monarch Platform was featured on the cover of the March-April 2019 issue of Oncology Issues. The journal, which is the official journal of the Association of Community Cancer Centers, was created for multidisciplinary oncology teams to provide information on a range of topics in cancer care. In the March-April issue of the journal, the Monarch Platform was featured in an article titled ...
-
Moffitt Cancer Center Advances Patient Standard of Care by Introducing Needleless Blood Draws
Moffitt Cancer Center has adopted a new needle-free method of blood collection for patients in treatment who often need to undergo repeated needle sticks in a day, becoming the first cancer center in Florida to offer this pain-free technology as part of its world-class cancer care. In its continuing efforts of being at the forefront of innovation, last year the cancer center piloted the ...
-
Collaboration with LOVIT/ Dr. Antonio Marchini
Redbiotec is pleased to announce the appointment of Dr. Antonio Marchini, head of Laboratory of Oncolytic-Virus-Immuno-Therapeutics (LOVIT) at the Luxembourg Institute of Health and German Cancer Research Center (DKFZ), as a member of our Scientific Advisory Board. Antonio is an expert in the field of oncolytic viruses aiming at developing innovative anticancer agents. Redbiotec looks forward to ...
By Redbiotec AG
-
Biopticon Reaches Milestone in Market Adoption
Biopticon Corporation reaches milestone in market adoption of their innovative Tumor Management System for preclinical oncology studies. Innovative instrument and software create revolutionary system to improve data, work-flow and results from in vivo cancer models Princeton, NJ Biopticon today announced that it had met its first milestone for customer adoption of the revolutionary ...
-
Experienced Healthcare Leader Laurie Smith Joins Inspirata as Vice President of Product Strategy for Clinical Trial Matching
Oncology informatics company, Inspirata, is pleased to announce the recent addition of a new key member to the company’s leadership team. Effective October 3rd, 2022, Laurie Smith has joined as Vice President of Product Strategy – Clinical Trial Matching. Laurie will be primarily focused on enhancing Inspirata’s suite of clinical trial matching solutions. This includes ...
-
Ackerman Cancer Center Celebrates 2,000 Patients Treated with Proton Therapy
Ackerman Cancer Center (ACC), the world’s first and only physician-owned proton therapy center, has reached a significant milestone in cancer care with the treatment of their 2,000th proton therapy patient. The Mevion-equipped center treated its first proton therapy patient in April of 2015 and reached its 1,000th patient milestone in October of 2018. “Congratulations to the ...
-
Preventive Cancer Vaccine Trial Releases Two-Year Safety Evaluation
The Vaccine Against Canine Cancer Study (VACCS) trial (www.vaccs.org) reported its formal two-year evaluation of the safety of a vaccine to prevent cancer in healthy dogs. The largest interventional trial in dogs, it is sponsored by the Open Philanthropy Project, with additional support from Calviri, Inc., a biotech spinout from Arizona State University. The VACCS trial intends to enroll up to ...
By Calviri
-
SEngine Precision Medicine Partners with Vincere Cancer Center to Increase Access for First Responders to Get Personalized Cancer Treatments via the PARIS Test
SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine and Vincere Cancer Center in Scottsdale, Arizona are collaborating to provide more cancer patients with access to SEngine’s signature diagnostic test, the PARIS® Test. This collaboration, facilitated by Aspire Financial, LLC., will provide SEngine’s cutting-edge ...
-
BriaCell Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces today that it has added Mayo Clinic, Jacksonville, Florida as a clinical site in the Phase I/II study of BriaCell’s lead candidate, Bria-IMT, with Incyte’s PD-1 ...
-
St. Jude recognizes Kmart as partner of the year for its commitment to charitable giving
Kmart is being honored as "Partner of the Year" by St. Jude Children"s Research Hospital for its commitment to helping children live a longer and healthier life. For the past four years, Kmart has participated in the St. Jude Thanks and Giving fundraising campaign, an unprecedented union of celebrities, media, retail and corporate partners that asks consumers to "Give thanks for the healthy kids ...
-
NIH-funded researchers discover genetic link to mesothelioma
Scientists have found that individuals who carry a mutation in a gene called BAP1 are susceptible to developing two forms of cancer — mesothelioma, and melanoma of the eye. Additionally, when these individuals are exposed to asbestos or similar mineral fibers, their risk of developing mesothelioma, an aggressive cancer of the lining of the chest and abdomen, may be markedly increased. The ...
-
New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ GeneFusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods
Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the publication of a new study in the Journal of Molecular Diagnostics on the Idylla™ GeneFusion Assay (RUO) for rapid detection of targetable fusions involving ALK, ROS1, RET, and NTRK1/2/3 and MET exon 14 skipping mutations. The ...
By Biocartis NV
-
IMV Provides an Update on The VITALIZE Trial
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today provided an update on the open-label VITALIZE study evaluating its lead product maveropepimut-S (MVP-S) in combination ...
By IMV Inc.
-
Obsidian Therapeutics & MD Anderson announce strategic collaboration to accelerate advancement of novel engineered tumor infiltrating lymphocyte therapy (cytoTIL™) for solid tumors
Obsidian Therapeutics, Inc. and The University of Texas MD Anderson Cancer Center today announced a multi-year strategic collaboration designed to expedite the research and development of novel engineered tumor infiltrating lymphocytes (TILs) for the treatment of solid tumors. The agreement pairs Obsidian and its novel cytoDRiVE™ technology platform with MD Anderson’s extensive ...
-
C4 Imaging Announces First Prostate Cancer Treatment Utilizing Orion HDR MRI Markers
C4 Imaging LLC is pleased to announce the first prostate cancer treatment utilizing Orion, a novel medical device that’s designed to facilitate the use of MRI in improving the accuracy of treatment. The procedure was performed by Dr Peter Rossi at the Calaway Young Cancer Center in Glenwood Springs, Colorado. “We are thrilled to be first to use Orion HDR MRI Markers in the treatment ...
-
Camurus announces dosing initiated in Phase 3 study of CAM2029 in patients with neuroendocrine tumors
Camurus (NASDAQ STO: CAMX) today announces that dosing has been initiated in the company’s randomized, active-controlled Phase 3 study, SORENTO, which aims to evaluate the efficacy and safety of octreotide subcutaneous depot (CAM2029) in the treatment of patients with neuroendocrine tumors localized in the gastrointestinal tract or pancreas (GEP-NET). “There is a high unmet medical ...
By Camurus AB
-
GT Medical Technologies Wins Prestigious Innovator of the Year Award at the 2021 Governor`s Celebration of Innovation
GT Medical Technologies, Inc. today announced it was named a winner of the Innovator of the Year in the small company category at the 2021 Governor's Celebration of Innovation, presented live on stage by the Arizona Technology Council and the Arizona Commerce Authority on October 13. GT Medical Technologies received this accolade in recognition of GammaTile® Therapy, its Surgically Targeted ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you